☆ 4.7 Review

Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments

BLOOD (2023)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy

Aldostefano Porcari et al.

Summary: The study found that approximately 20.7% of elderly patients with ATTR-CM have a pathogenic TTR variant. Therefore, it is recommended that all patients diagnosed with ATTR-CM undergo routine sequencing of the TTR gene, regardless of age.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis A Report of the American College of Cardiology Solution Set Oversight Committee

Michelle M. Kittleson et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial

David Adams et al.

Summary: This study assessed the effectiveness of vutrisiran in patients with hereditary transthyretin amyloidosis. The results showed significant improvements in disease-relevant outcomes and an acceptable safety profile for vutrisiran.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2023)

Add to Collection

Article Medicine, General & Internal

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Pablo Garcia-Pavia et al.

Summary: NI006, a recombinant human anti-ATTR antibody, was found to be safe and effective in reducing the cardiac amyloid load in patients with ATTR cardiomyopathy and heart failure, according to a phase 1 trial.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Clinical Neurology

Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis

Luca Leonardi et al.

Summary: This study aimed to assess the role of skin biopsy as a marker of disease onset and severity in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). The results showed that skin amyloid deposits are a marker of ATTRv-PN disease onset, and decreased intraepidermal nerve fiber density (IENFD) is a marker of disease progression.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

TTR Gly83Arg Mutation: Beyond Familial Vitreous Amyloidosis

Zhenxian Li et al.

Summary: This study provides a detailed account of the extraocular presentations of Gly83Arg mutation-related ATTR in the Chinese population. The clinical features of this mutation include early-onset, ocular involvement predominance, neurological and cardiac involvement, and relatively long survival.

FRONTIERS IN NEUROLOGY (2022)

Add to Collection

Article Surgery

Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation

Hartmut H. Schmidt et al.

Summary: This study evaluated the efficacy and safety of patisiran in patients with ATTRv amyloidosis with polyneuropathy progression following liver transplantation. The results showed that patisiran reduced serum TTR levels, improved neuropathy and quality of life, and stabilized disability and nutritional status. Most patients had normal liver function. Patisiran treatment was well tolerated.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis

Yukio Ando et al.

Summary: The recent approval of drugs for the treatment of ATTR amyloidosis has opened a new era in care and changed the therapeutic strategy. The drugs target critical steps of the amyloid cascade and show clinical effectiveness. However, without comparative trials, it is difficult to make specific recommendations.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis

Steven Law et al.

Summary: This study observed 879 patients with ATTR-CM and found that patients with NAC ATTR Stage Ia disease had significant cardiovascular morbidity despite good short- and mid-term survival. The concentration of NT-proBNP and diuretic requirement at diagnosis can be used to further stratify patients with NAC ATTR Stage I ATTR-CM.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Clinical Neurology

Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy

Marco Luigetti et al.

Summary: This article presents the long-term outcomes of Italian ATTRv patients who received inotersen within an early-access program. The study found that inotersen has a favorable safety profile and that the severity of neurologic disease at baseline is the main factor associated with disease progression.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Cerebellar and Cerebral Amyloid Visualized by [18F]flutemetamol PET in Long-Term Hereditary V30M (p.V50M) Transthyretin Amyloidosis Survivors

Erica Irene Uneus et al.

Summary: This study found that amyloid deposition within the brain is common in long-term survivors of ATTRv amyloidosis, especially in the cerebellum. A cerebellar amyloid uptake profile seems to be related to TFNE symptoms.

FRONTIERS IN NEUROLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis

John K. Diep et al.

Summary: The aim of this study was to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model for eplontersen and evaluate the impact of covariates on exposure and response. The results showed that weight and injection site affected systemic exposure, but this effect did not seem to result in clinically relevant variation in response.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Add to Collection

Article Genetics & Heredity

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update

Angela Dispenzieri et al.

Summary: This study provides a 14-year global overview of transthyretin amyloidosis, including over 5000 patients, highlighting the genotypic and phenotypic heterogeneity of the disease.

ORPHANET JOURNAL OF RARE DISEASES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism

Chiara Sanguinetti et al.

Summary: This article provides an overview of the biological life cycle of transthyretin (TTR), including its physiological metabolism and the role of mutations and physiological ligands in its stability. Understanding these mechanisms is crucial for a better comprehension of the pathogenesis of TTR amyloidosis.

BIOMEDICINES (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years

Adam Ioannou et al.

Summary: There has been significant progress in the diagnosis of transthyretin cardiac amyloidosis (ATTR-CA) over the past 20 years. The number of ATTR-CA diagnoses has increased over time, with more patients being diagnosed at an early stage of the disease and experiencing lower mortality rates.

CIRCULATION (2022)

Add to Collection

Article Ophthalmology

Transthyretin proteoforms of intraocular origin in human subretinal fluid

Jianzhong Chen et al.

Summary: Understanding the protein composition of subretinal fluid could lead to new treatment strategies for blindness. The study found that subretinal fluid contains abundant proteins, with transthyretin (TTR) being one of the major proteins. The research also highlighted the importance of glutathionylation in the normal function of TTR.

EXPERIMENTAL EYE RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee

Joel N. Buxbaum et al.

Summary: The Nomenclature Committee of the International Society of Amyloidosis has proposed a nomenclature recommendation, adding six new proteins to the list of human amyloid fibril proteins, including intracellular amyloid fibrils associated with neurodegenerative diseases.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

Bahru A. Habtemariam et al.

Summary: Vutrisiran demonstrated potent and sustained reduction of TTR in healthy subjects, with favorable pharmacokinetics and safety profile. The results were similar in Japanese and non-Japanese subjects.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Clinical Neurology

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams et al.

Summary: Hereditary transthyretin-mediated amyloidosis is a rare genetic disease caused by mutations in the TTR gene. Long-term treatment with patisiran, an RNA interference therapeutic, showed sustained efficacy and acceptable safety profile in patients with this condition, as demonstrated in a 12-month interim analysis of a global open-label extension study.

LANCET NEUROLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

Nicholas J. Viney et al.

Summary: AKCEA-TTR-L-Rx, a ligand-conjugated antisense drug, showed significantly increased potency compared to unconjugated inotersen in human hepatocyte cell culture and transgenic hTTR mice expressing a mutated human genomic TTR sequence. In a phase 1 study with healthy volunteers, AKCEA-TTR-L-Rx demonstrated a reduction in TTR levels and a favorable safety profile, supporting its further development for the treatment of ATTR polyneuropathy and cardiomyopathy.

ESC HEART FAILURE (2021)

Add to Collection

Review Clinical Neurology

CNS Involvement in Hereditary Transthyretin Amyloidosis

Luisa Sousa et al.

Summary: Hereditary transthyretin amyloidosis primarily affects the peripheral nerves, heart, kidney, and eye, but recent studies have shown increasing involvement of the central nervous system. Symptoms of CNS dysfunction are becoming more apparent in patients with this condition, indicating that it may become a significant issue in patient management in the future.

NEUROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

Julian D. Gillmore et al.

Summary: The gene-editing therapeutic agent NTLA-2001 effectively reduced serum TTR protein concentrations in patients with ATTR amyloidosis, showing potential safety and pharmacodynamic effects in clinical studies.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells

Aubin Michalon et al.

Summary: Through analyzing memory B cell repertoires of healthy elderly, researchers developed a selective human antibody that removes cardiac amyloid by recruiting phagocytic immune cells.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry

Margaret M. Parker et al.

Summary: Carriers of the V122I mutation exhibit a higher risk of polyneuropathy in the UK Biobank, Penn Medicine Biobank, and Million Veteran Program. This underscores the underdiagnosis of hereditary transthyretin-mediated amyloidosis in V122I carriers and the importance of understanding the manifestations associated with this mutation for earlier diagnosis and treatment.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Clinical Neurology

Current Review of Leptomeningeal Amyloidosis Associated With Transthyretin Mutations

Qi Qin et al.

Summary: Leptomeningeal amyloidosis (LA) is a rare subtype of familial transthyretin (TTR) amyloidosis characterized by cognitive impairment, headache, ataxia, and neurological symptoms in patients. Elevated high CSF protein level is shown in CSF analysis, while MRI examination reveals extensive leptomeningeal enhancement.

NEUROLOGIST (2021)

Add to Collection

Article Clinical Neurology

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Teresa Coelho et al.

Summary: AKCEA-TTR-L-Rx is a ligand-conjugated antisense drug being developed for the treatment of hereditary transthyretin amyloidosis. It utilizes a triantennary N-acetylgalactosamine moiety to increase drug potency for lower and less frequent dosing. The NEURO-TTRansform study aims to evaluate the efficacy of AKCEA-TTR-L-Rx in improving neurologic function and quality of life for hATTR-PN patients.

NEUROLOGY AND THERAPY (2021)

Add to Collection

Correction Clinical Neurology

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study (vol 20, pg 49, 2021)

D. Adams et al.

LANCET NEUROLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers

Jonathan C. Fox et al.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

Daniel P. Judge et al.

CARDIOVASCULAR DRUGS AND THERAPY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Jessica E. Sutherland et al.

NUCLEIC ACID THERAPEUTICS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients

Orly Moshe-Lilie et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Investigating the pharmacodynamic durability o f GalNAc-siRNA conjugates

Christopher R. Brown et al.

NUCLEIC ACIDS RESEARCH (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy

Daniel P. Judge et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis The APOLLO Study

Masatoshi Minamisawa et al.

JAMA CARDIOLOGY (2019)

Add to Collection

Article Clinical Neurology

Burden of hereditary transthyretin amyloidosis on quality of life

Aaron Yarlas et al.

MUSCLE & NERVE (2019)

Add to Collection

Review Clinical Neurology

Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease

David Adams et al.

NATURE REVIEWS NEUROLOGY (2019)

Add to Collection

Review Clinical Neurology

Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS+7

P. James B. Dyck et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study

Scott D. Solomon et al.

CIRCULATION (2019)

Add to Collection

Letter Medicine, General & Internal

Tafamidis for Transthyretin Amyloid Cardiomyopathy

Christopher Manion et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, Research & Experimental

Predictive model of response to tafamidis in hereditary ATTR polyneuropathy

Ceclia Monteiro et al.

JCI INSIGHT (2019)

Add to Collection

Article Clinical Neurology

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy

Hartmut H. Schmidt et al.

MUSCLE & NERVE (2018)

Add to Collection

Article Medicine, General & Internal

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

D. Adams et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

M. D. Benson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Biochemistry & Molecular Biology

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics

Aaron D. Springer et al.

NUCLEIC ACID THERAPEUTICS (2018)

Add to Collection

Article Medicine, General & Internal

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Mathew S. Maurer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy

Vincent Algalarrondo et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2018)

Add to Collection

Article Clinical Neurology

Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy

Teresa Coelho et al.

NEUROLOGY (2018)

Add to Collection

Letter Clinical Neurology

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy

Andrea Cortese et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model

Paula Goncalves et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides

Elizabeth J. Ackermann et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis

Julian D. Gillmore et al.

CIRCULATION (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis

Jason N. Dungu et al.

CIRCULATION-HEART FAILURE (2016)

Add to Collection

Article Chemistry, Medicinal

Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes

Thazha P. Prakash et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

Add to Collection

Article Clinical Neurology

Genotype-Phenotype Correlation and Course of Transthyretin Familial Amyloid Polyneuropathies in France

Louise-Laure Mariani et al.

ANNALS OF NEUROLOGY (2015)

Add to Collection

Article Clinical Neurology

Rapid progression of familial amyloidotic polyneuropathy A multinational natural history study

David Adams et al.

NEUROLOGY (2015)

Add to Collection

Article Immunology

Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?

Bo-Goran Ericzon et al.

TRANSPLANTATION (2015)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Prediction of Long-Term Survival After Liver Transplantation for Familial Transthyretin Amyloidosis

Vincent Algalarrondo et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)

Add to Collection

Article Genetics & Heredity

Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations

Dorota M. Rowczenio et al.

HUMAN MUTATION (2014)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Identification of TTR-Related Subclinical Amyloidosis With 99mTc-DPD Scintigraphy

Simone Longhi et al.

JACC-CARDIOVASCULAR IMAGING (2014)

Add to Collection

Article Clinical Neurology

Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy

P. Lozeron et al.

EUROPEAN JOURNAL OF NEUROLOGY (2013)

Add to Collection

Article Medicine, General & Internal

Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial

John L. Berk et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis

Teresa Coelho et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Clinical Neurology

Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas

Haruki Koike et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)

Add to Collection

Article Clinical Neurology

Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial

Teresa Coelho et al.

NEUROLOGY (2012)

Add to Collection

Meeting Abstract Biochemistry & Molecular Biology

Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy

L. H. Connors et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2011)

Add to Collection

Article Biochemistry & Molecular Biology

Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment

Merrill D. Benson et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2010)

Add to Collection

Article Genetics & Heredity

Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)

Gösta Holmgren et al.

CLINICAL GENETICS (2010)

Add to Collection

Article Clinical Neurology

Progression of transthyretin amyloid neuropathy after liver transplantation

Juris J. Liepnieks et al.

NEUROLOGY (2010)

Add to Collection

Article Clinical Neurology

Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan - Early-vs late-onset form

H Koike et al.

ARCHIVES OF NEUROLOGY (2002)

Add to Collection

Article Clinical Neurology

The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation

D Adams et al.

BRAIN (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.